Needham, Massachusetts, United States · Est. 1983
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies and targeted therapies for cancer and other diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 3
R&D Momentum
41/100
Pipeline Velocity
15/100
Trial Completion Rate
74/100
Pipeline Concentration
33/100
Pipeline Freshness
85/100
Strategic Signals
Activity
Details
Company Overview
—
Mkt Cap
$1.5M
Revenue
$28.4M
Cash
Therapeutic Focus
Recent SEC Filings
FORM 8-K
FORM 8-K
FORM 8-K
Celldex Therapeutics, Inc. (CLDX) (CIK 0000744218)
Pipeline
Regulatory
FORM 8-K
Accession: 0001171843-26-005316
FORM 8-K
Accession: 0001104659-26-083880
FORM 8-K
Accession: 0001104659-26-078023
Celldex Therapeutics, Inc. (CLDX) (CIK 0000744218)
Accession: 000-15006
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)